诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

盘后交易 07-24 18:36:10 EDT

131.60

-1.68

-1.26%

盘后131.50

-0.10-0.08%

18:35 EDT

最高132.90	最低130.92	成交量265.10万
今开132.50	昨收133.28	日振幅1.49%
总市值5,836亿	流通市值4,170亿	总股本44.35亿
成交额3.49亿	换手率0.08%	流通股本31.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":131.6,"timestamp":1721851200000,"preClose":133.28,"halted":0,"volume":2650991,"hourTrading":{"tag":"盘后","latestPrice":131.5,"preClose":131.6,"latestTime":"18:35 EDT","volume":17574,"amount":2311984.6511399997,"timestamp":1721860539389},"delay":0,"floatShares":3168321847,"shares":4434515173,"eps":2.879408,"marketStatus":"盘后交易","marketStatusCode":4,"change":-1.68,"latestTime":"07-24 18:36:10 EDT","open":132.5,"high":132.9,"low":130.92,"amount":349179441.62087,"amplitude":0.014856,"askPrice":132.25,"askSize":7,"bidPrice":131.03,"bidSize":5,"shortable":3,"etf":0,"ttmEps":2.879408,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721865600000},"adr":1,"listingDate":363499200000,"adjPreClose":133.28,"adrRate":1,"dividendRate":0.010512,"preHourTrading":{"tag":"盘前","latestPrice":132.48,"preClose":133.28,"latestTime":"09:29 EDT","volume":15275,"amount":2020493.5985,"timestamp":1721827799067},"postHourTrading":{"tag":"盘后","latestPrice":131.5,"preClose":131.6,"latestTime":"18:35 EDT","volume":17574,"amount":2311984.6511399997,"timestamp":1721860539389},"volumeRatio":0.49302,"optionData":{"bulkOrders":[{"symbol":"NVO","call":true,"expireDate":1726804800000,"strike":"160.0","timestamp":1721838875677,"price":0.75,"volume":4778,"amount":358350,"type":"+"}]},"impliedVol":0.3924,"impliedVolPercentile":0.8929},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2453013741","title":"诺和诺德(NVO.US)减肥药Wegovy获得英国监管部门批准 可用于治疗心脏病","url":"https://stock-news.laohu8.com/highlight/detail?id=2453013741","media":"智通财经","labels":["Product Release","Policy And Regulatory"],"top":1,"share":"https://www.laohu8.com/m/news/2453013741?lang=zh_cn&edition=full","pubTime":"2024-07-24 08:45","pubTimestamp":1721781900,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，继美国之后，英国监管部门也批准扩大诺和诺德减肥药Wegovy的适用范围至治疗心脏病。该减肥药成为该国首个用于预防肥胖人群心血管事件的处方药。诺和诺德的重磅产品Wegovy注射剂已经在英国获得批准，用于治疗肥胖和体重管理，与饮食、体育活动和行为支持一起使用。然而，新的批准标志着该公司寻求摆脱Wegovy作为“虚荣药”的形象，并抵御日益激烈的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"减肥药Wegovy获批预防心脏病 诺和诺德再下一城","news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4532","BK4007","NVO","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","BK4588"],"gpt_icon":1},{"id":"2453068787","title":"诺和诺德拟在丹麦新建工厂 或用于扩大减肥药产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2453068787","media":"媒体滚动","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453068787?lang=zh_cn&edition=full","pubTime":"2024-07-24 01:17","pubTimestamp":1721755062,"startTime":"0","endTime":"0","summary":"财联社7月23日讯 当地时间周二，丹麦制药巨头诺和诺德宣布，本月早些时候在丹麦第三大城市欧登塞买下了一块200英亩的土地，并获得了规划许可。虽然诺和诺德并未透露这块土地的用途，但从已有信息来看，该公司可能会将其用于扩大减肥药的产能。丹麦去年经济增长了近2%，但如果没有诺和诺德的贡献，丹麦经济可能会停滞不前。","market":"us","thumbnail":"https://n.sinaimg.cn/finance/transform/162/w550h412/20240724/1d69-d0a310409cadb7ec1bab5a36700d963a.jpg","type":0,"news_type":0,"thumbnails":["https://n.sinaimg.cn/finance/transform/162/w550h412/20240724/1d69-d0a310409cadb7ec1bab5a36700d963a.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2024-07-23/doc-incfeeas7757129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IE00BKVL7J92.USD","LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4532","BK4007","LU0154236417.USD","BK4585","NVO"],"gpt_icon":1},{"id":"2453034143","title":"诺和诺德(NVO)或在丹麦新建工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2453034143","media":"金吾财讯","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453034143?lang=zh_cn&edition=full","pubTime":"2024-07-23 21:07","pubTimestamp":1721740031,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVN)宣布，已成功获取了位于丹麦第三大城市奥登塞的一块土地及其规划批准，用于建设其下一个重要的生产设施，此举旨在应对其减肥药品需求的急剧增长。该公司在本月初与奥登塞市政府达成了土地购买协议，并在市政府批准其规划方案后，成功购入了约200英亩的土地。诺和诺德的一位发言人透露，公司计划很快在这片土地上启动前期的挖掘工程。同时，该发言人还指出，在经过公司内部的评估之后，预计将在今年年底前对是否在新地点进行投资做出最终决策。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278110","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","BK4532","LU0154236417.USD","BK4585","BK4007","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4588","LU1093756168.USD"],"gpt_icon":1},{"id":"2453008209","title":"诺和诺德(NVO.US)或在丹麦新建工厂 已获得土地及规划许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2453008209","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453008209?lang=zh_cn&edition=full","pubTime":"2024-07-23 18:52","pubTimestamp":1721731941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德周二表示，该公司已经为其在丹麦第三大城市Odense的下一个主要工厂获得了土地和规划许可，以满足市场对其减肥药不断飙升的需求。诺和诺德一位发言人表示，该公司将很快开始在该地点进行预备挖掘工作。诺和诺德尚未透露该新址的用途。据悉，诺和诺德正努力增加其降糖药和减肥药的供应。今年6月，诺和诺德表示，预计今年将在生产上投资68亿美元，高于2023年的39亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4007","BK4585","NVO","LU1093756168.USD","BK4532","BK4588"],"gpt_icon":1},{"id":"2453705500","title":"诺和诺德在丹麦欧登塞购置地块，有望年底做出最终投资决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2453705500","media":"界面","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453705500?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:53","pubTimestamp":1721717603,"startTime":"0","endTime":"0","summary":"7月23日消息，诺和诺德于本月初在丹麦第三大城市欧登塞购买了一块200英亩的土地。诺和诺德发言人示，公司将很快开始在该地块南部启动准备性挖掘工作，经过内部审查后，公司将于今年年底就是否投资新地块做出最终决定。（彭博）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723145323af93940b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723145323af93940b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU0154236417.USD","LU1093756168.USD","NVO","BK4588","BK4585","IE00BZ1G4Q59.USD","BK4007","BK4532","LU1093756325.SGD"],"gpt_icon":0},{"id":"2453772496","title":"诺和诺德或将在丹麦再建一座工厂，已获得土地和规划许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2453772496","media":"环球市场播报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453772496?lang=zh_cn&edition=full","pubTime":"2024-07-23 13:43","pubTimestamp":1721713413,"startTime":"0","endTime":"0","summary":"$诺和诺德$公司已经为其在丹麦的下一个主要工厂获得了土地和规划许可，以满足对其减肥药不断飙升的需求。诺和诺德正积极增加其糖尿病和减肥药物的供应。在过去的14个月里，该公司已宣布在丹麦、法国和美国投资数十亿美元扩建工厂。欧登塞距离丹麦首都哥本哈根只有大约两个小时的车程，这将是诺和诺德的一个新地点。该工厂距离Kalundborg不到60英里，后者是诺和诺德畅销药物Ozempic和Wegovy的关键原料生产地。","market":"us","thumbnail":"https://static.tigerbbs.com/bde7ae9d5c597eb01bbb4658f0573654","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bde7ae9d5c597eb01bbb4658f0573654"],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-23/doc-incfawif0448260.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-23/doc-incfawif0448260.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["NVO"],"gpt_icon":0},{"id":"2453768407","title":"美股减肥药板块走势分化 诺和诺德(NVO.US)、礼来(LLY.US)双头垄断格局面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2453768407","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453768407?lang=zh_cn&edition=full","pubTime":"2024-07-22 18:50","pubTimestamp":1721645400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月以来，美股减肥药板块走势分化。市场领导者诺和诺德、礼来股价均走低，而实力较强的追赶者罗氏、辉瑞、安进在7月分别累计上涨13%、7%和6%。诺和诺德将于美东时间8月8日公布第二季度业绩。市场对减肥药的火爆需求推动诺和诺德第一季度净利润同比增长28%，该公司还上调了全年营收与经营利润增速指引。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0471298694.HKD","LU0114720955.EUR","BK4534","LU0823416689.USD","LU0882574055.USD","IE00BJT1NW94.SGD","IE00BJLML261.HKD","LU0385154629.USD","IE00B1BXHZ80.USD","IE00BJJMRZ35.SGD","BK4585","GB00BDT5M118.USD","LU0094547139.USD","LU1551013342.USD","BK4516","LU0109391861.USD","LU1069344957.HKD","IE0009355771.USD","PFE","LU1093756168.USD","LU1280957306.USD","BK4532","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0079474960.USD","LU0882574139.USD","LU0061475181.USD","LU0466842654.USD","LU1623119135.USD","BK4007","LU1035775433.USD","IE0002141913.USD","LU0708995401.HKD","LU0820561909.HKD","LU0820561818.USD","LU1712237335.SGD","LU0689472784.USD","LU1551013425.SGD","BK4533","IE00BKVL7J92.USD","IE0004445239.USD","LU0256863811.USD","LU1093756325.SGD","LU0096364046.USD","LU1061106388.HKD","LLY","NVO","LU0943347566.SGD","LU0097036916.USD","LU1804176565.USD"],"gpt_icon":1},{"id":"2453786850","title":"最高减重20%！礼来“替尔泊肽”在华获批，效果强过司美格鲁肽？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453786850","media":"格隆汇","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453786850?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:20","pubTimestamp":1721614814,"startTime":"0","endTime":"0","summary":"竞争白热化？","market":"us","thumbnail":"https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/869192","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["IE0002141913.USD","000963","LU1093756168.USD","BK0175","BK4534","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","LU0385154629.USD","LU0820561909.HKD","BK4007","BK0077","300199","LU1623119135.USD","LU0061475181.USD","BK0239","LU0094547139.USD","LU2328871848.SGD","LU0109391861.USD","LU0097036916.USD","LU1551013425.SGD","LU0471298694.HKD","LU0058720904.USD","LU0122379950.USD","BK0188","BK4533","LU1093756325.SGD","LI","LU0943347566.SGD","LU1035775433.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","BK4532","LU0256863811.USD","LU0096364046.USD","LU0882574055.USD","BK4516","LU1280957306.USD","LU1551013342.USD","NVO","LU0114720955.EUR","LU0079474960.USD","BK0187","LU0708995401.HKD","BK0183","IE0009355771.USD","IE0004445239.USD","GB00BDT5M118.USD","603087","IE00BJLML261.HKD","LU1804176565.USD"],"gpt_icon":1},{"id":"2452062894","title":"减肥药赛道“搅局者”来了，两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452062894","media":"中国基金报","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452062894?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:16","pubTimestamp":1721405811,"startTime":"0","endTime":"0","summary":"国内减重赛道迎来重磅级“选手”。7月19日，记者从国家药品监督管理局获悉，礼来的替尔泊肽注射液长期体重管理适应证获得批准，这是目前首个且是唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。一直以来，礼来与诺和诺德并称“GLP-1双雄”，后者拥有“减肥神药”司美格鲁肽，已在国内获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407203135777061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407203135777061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LLY","NVO","BK4007","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","BK4588","IE00BZ1G4Q59.USD","BK4532","BK4585"],"gpt_icon":1},{"id":"2452742784","title":"司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2452742784","media":"每日经济新闻","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452742784?lang=zh_cn&edition=full","pubTime":"2024-07-19 22:16","pubTimestamp":1721398617,"startTime":"0","endTime":"0","summary":"7月19日，礼来宣布，穆峰达（替尔泊肽注射液）长期体重管理适应症获得国家药品监督管理局（NMPA）批准。据介绍，穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135753480.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135753480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0094547139.USD","LU1804176565.USD","NVO","BK4533","LU0882574055.USD","LU0256863811.USD","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","IE0004445239.USD","LU1551013342.USD","BK4581","BK4534","LU1280957306.USD","LLY","GB00BDT5M118.USD","LU1551013425.SGD","LU1267930730.SGD","LU0456855351.SGD","BK4588","BK4585","LU0471298694.HKD","LU0471298777.SGD","LU0289739699.SGD","LU0079474960.USD","LU0198837287.USD","LU0943347566.SGD","LU0061475181.USD","LU0320765059.SGD","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1023059063.AUD","LU1035775433.USD","LU0708995401.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0256863902.USD","IE00B2B36J28.USD","LU0122379950.USD","LU0640476718.USD","IE00BK4W5L77.USD","LU0058720904.USD","LU0417517546.SGD","BK4007","LU1061106388.HKD","LU0114720955.EUR","LU0238689110.USD","IE00BJLML261.HKD","LU0109391861.USD","LU0672654240.SGD","IE00B4R5TH58.HKD","LU1064131342.USD"],"gpt_icon":1},{"id":"2452420474","title":"BUZZ-减肥药在中国获批，礼来公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2452420474","media":"Reuters","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452420474?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:29","pubTimestamp":1721392190,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    7月19日 - ** 礼来  股价盘前上涨2.4%至866.75美元 ** 公司称 (link) 其减肥药替西帕肽已获得中国监管机构的批准 ** 蒂塞帕肽是这家美国制药商的糖尿病药物Mounjaro（也在中国获批）和减肥药物Zepbound的活性成分** 礼来公司和丹麦制药商诺和诺德  在增加减肥药产量的竞争中遥遥领先，预计到2030年代初，减肥药市场将达到约1500亿美元的规模 (link)。** 截至上次收盘，该股今年累计上涨45.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4007","LU1061106388.HKD","BK4533","LU0079474960.USD","LU0109391861.USD","LU0256863811.USD","LU0094547139.USD","LU0708995401.HKD","LU0058720904.USD","LU0820561818.USD","LU0689472784.USD","LU0114720955.EUR","IE00B2B36J28.USD","LLY","LU0823416689.USD","LU0943347566.SGD","LU0122379950.USD","GB00BDT5M118.USD","BK4534","LU1064131342.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0882574139.USD","LU1551013425.SGD","LU0471298694.HKD","NVO","LU0096364046.USD","LU1551013342.USD","IE00BJLML261.HKD","BK4585","IE00B1BXHZ80.USD","LU1069344957.HKD","IE0004445239.USD","LU1623119135.USD","LU1804176565.USD","IE00B4R5TH58.HKD","LU0820561909.HKD","IE00BJJMRZ35.SGD","BK4516","LU1280957306.USD","LU0097036916.USD","LU0061475181.USD","LU1035775433.USD","LU0640476718.USD","LU0198837287.USD","LU0466842654.USD","LU1712237335.SGD","IE00BFTCPJ56.SGD","LU0385154629.USD","IE0002141913.USD"],"gpt_icon":1},{"id":"2452478682","title":"礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2452478682","media":"老虎证券","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452478682?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:16","pubTimestamp":1721391360,"startTime":"0","endTime":"0","summary":"【礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争】智通财经APP获悉，7月19日，礼来(LLY.US)穆峰达®(替尔泊肽注射液)长期体重管理适应症获得中国国家药品监督管理局(NMPA)批准。穆峰达®是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192018579f6b9b35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192018579f6b9b35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0097036916.USD","BK4581","LU0471298694.HKD","LU1057294990.SGD","LU0882574055.USD","LU0109391861.USD","LU0256863811.USD","LU1551013425.SGD","IE00BJT1NW94.SGD","LU0320765059.SGD","LU1280957306.USD","BK4533","IE00BK4W5M84.HKD","LU0289739699.SGD","IE00B1BXHZ80.USD","LU0096364046.USD","LU0058720904.USD","LU0122379950.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU1035775433.USD","IE00BK4W5L77.USD","LU0708995401.HKD","IE00BJLML261.HKD","BK4534","IE00BZ1G4Q59.USD","GB00BDT5M118.USD","LU0672654240.SGD","LU1093756325.SGD","LU0256863902.USD","BK4588","BK4532","LU0238689110.USD","LU1061106388.HKD","LU1551013342.USD","NVO","LU1804176565.USD","BK4516","IE0004445239.USD","LU1093756168.USD","LU0114720955.EUR","LU0079474960.USD","IE0002141913.USD","LU0417517546.SGD","LU0943347566.SGD","BK4007","LU0094547139.USD","LU0154236417.USD","LU0061475181.USD","LLY"],"gpt_icon":1},{"id":"2452080424","title":"礼来替尔泊肽获批减重新适应症，GLP-1赛道掀王者之争孰胜孰负？","url":"https://stock-news.laohu8.com/highlight/detail?id=2452080424","media":"21世纪经济报道","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452080424?lang=zh_cn&edition=full","pubTime":"2024-07-19 19:25","pubTimestamp":1721388307,"startTime":"0","endTime":"0","summary":"7月19日，国家药品监督管理局（NMPA）官网显示，礼来的葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体双重激动剂Mounjaro（Tirzepatide，替尔泊肽）新适应症获批上市，用于在低热量饮食和增加运动基础上改善成人肥胖或伴有至少一种体重相关合并症的超重患者长期体重管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135667664.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135667664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","BK4534","IE00BFTCPJ56.SGD","GB00BDT5M118.USD","LU0882574139.USD","LU1061106388.HKD","LU1023059063.AUD","IE00BJLML261.HKD","IE00BJT1NW94.SGD","LU0058720904.USD","LU0079474960.USD","LU0122379950.USD","IE0004445239.USD","LU1035775433.USD","IE00BJJMRZ35.SGD","LU0061475181.USD","BK4585","LU0114720955.EUR","LU0882574055.USD","LU0256863811.USD","LU1280957306.USD","LU1804176565.USD","LU0689472784.USD","LU0708995401.HKD","LU0943347566.SGD","LU1064131342.USD","GLP","LU0097036916.USD","IE0009355771.USD","LU0466842654.USD","BK4007","IE00B1BXHZ80.USD","BK4516","BK4533","LU1712237335.SGD","LU0096364046.USD","LU1551013425.SGD","LU0820561909.HKD","LU0109391861.USD","LU1057294990.SGD","LU1069344957.HKD","LU1551013342.USD","LU0289739699.SGD","LU0385154629.USD","LU0823416689.USD","IE0002141913.USD","LU1623119135.USD","LU0094547139.USD","LLY","LU0820561818.USD","LU0471298694.HKD"],"gpt_icon":1},{"id":"2452441340","title":"礼来公司的减肥药替西帕肽在中国获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452441340","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452441340?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:40","pubTimestamp":1721378400,"startTime":"0","endTime":"0","summary":"诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 。礼来公司的发言人没有立即回应关于该公司的药品何时开始在中国销售或将供应多少剂量的置评请求。美国礼来公司的糖尿病药物蒙加罗和减肥药物Zepbound的活性成分都是替齐帕特，蒙加罗也已在中国获批 。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0943347566.SGD","LU0385154629.USD","LU0820561818.USD","LU1712237335.SGD","LU0289739699.SGD","LU0094547139.USD","LU0708995401.HKD","LU0256863811.USD","LU0114720955.EUR","IE00BK4W5L77.USD","LU0689472784.USD","BK4007","BK4534","LU0471298694.HKD","BK4533","LU0097036916.USD","LU0672654240.SGD","LU0882574055.USD","LLY","LU1061106388.HKD","IE00BJT1NW94.SGD","IE00B1BXHZ80.USD","LU1023059063.AUD","LU1551013342.USD","IE00BK4W5M84.HKD","BK4588","NVO","IE00BJLML261.HKD","LU0882574139.USD","GB00BDT5M118.USD","LU0079474960.USD","LU1057294990.SGD","LU1623119135.USD","IE0004445239.USD","LU1804176565.USD","IE0002141913.USD","BK4581","LU0109391861.USD","LU1035775433.USD","LU1551013425.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0122379950.USD","IE0009355771.USD","LU0466842654.USD","LU1280957306.USD","LU1069344957.HKD","LU0058720904.USD","LU0820561909.HKD","LU0096364046.USD"],"gpt_icon":1},{"id":"1110119848","title":"诺和诺德、礼来均跌超5%！“减肥药双雄”连续两个交易日大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1110119848","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1110119848?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:12","pubTimestamp":1721315557,"startTime":"0","endTime":"0","summary":"7月18日，$诺和诺德(NVO)$、$礼来(LLY)$均跌超5%，“减肥药双雄”连续两个交易日大跌。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU0471298694.HKD","NVO.AU","LU1064131342.USD","IE00BKVL7J92.USD","LU1551013425.SGD","LU0689472784.USD","LU0097036916.USD","BK4532","NVO","LU0122379950.USD","LU1061106388.HKD","LLY","IE00B1BXHZ80.USD","LU0466842654.USD","LU0096364046.USD","LU0882574055.USD","LU1035775433.USD","BK4585"],"gpt_icon":0},{"id":"2452433561","title":"诺和诺德盘中异动 早盘股价大跌5.03%报128.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452433561","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452433561?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:04","pubTimestamp":1721315063,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日23时04分，诺和诺德股票出现异动，股价急速跳水5.03%。截至发稿，该股报128.61美元/股，成交量331.777万股，换手率0.07%，振幅4.73%。诺和诺德股票所在的生物技术行业中，整体跌幅为1.51%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。目前，在全球范围内，唯一获批的口服GLP-1制剂就是诺和诺德旗下的司美格鲁肽片剂Rybelsus。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718230424aefa5998&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718230424aefa5998&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4532","NVO","LU0154236417.USD","BK4007","BK4585"],"gpt_icon":1},{"id":"2452119261","title":"行业巨震！罗氏新药 “吓坏”减肥药板块 礼来与诺和诺德应声下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2452119261","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452119261?lang=zh_cn&edition=full","pubTime":"2024-07-18 08:00","pubTimestamp":1721260800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在瑞士制药巨头罗氏宣布其口服减肥药临床试验取得积极结果后，礼来与诺和诺德股价周三下跌。罗氏周三表示，收购Carmot Therapeutics获得的第二种候选药物显示出积极的效果，这进一步加剧了减肥药市场的竞争。截至周三美股收盘，罗氏上涨7.53%，Wegovy生产商诺和诺德下跌3.87%，Zepbound生产商礼来下跌3.82%，减肥药新贵Viking Therapeutics下跌12.56%。今年1月，罗氏完成了对减肥药开发商Carmot Therapeutics的收购。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152376.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0154236417.USD","LU0256863902.USD","LU0289739699.SGD","LU1061106388.HKD","LU0456855351.SGD","LU0820561909.HKD","LU0238689110.USD","LU0385154629.USD","LU1551013342.USD","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1069344957.HKD","IE00BZ1G4Q59.USD","IE0002141913.USD","LLY","LU0256863811.USD","LU0417517546.SGD","IE0009355771.USD","LU0466842654.USD","LU0882574139.USD","BK4581","LU0096364046.USD","LU0471298777.SGD","LU1064131342.USD","IE00BK4W5L77.USD","LU1804176565.USD","IE00BKVL7J92.USD","LU0320765059.SGD","LU0689472784.USD","LU0097036916.USD","BK4516","LU1623119135.USD","LU0943347566.SGD","IE00BK4W5M84.HKD","NVO","LU1267930730.SGD","LU1712237335.SGD","BK4585","GB00BDT5M118.USD","LU0823416689.USD","LU0672654240.SGD","LU0198837287.USD","LU0640476718.USD","LU0079474960.USD","LU0114720955.EUR","LU0820561818.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2452071163","title":"背景资料-减肥药开发商排队开发价值 1500 亿美元的市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2452071163","media":"Reuters","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452071163?lang=zh_cn&edition=full","pubTime":"2024-07-17 22:51","pubTimestamp":1721227909,"startTime":"0","endTime":"0","summary":"Wegovy与诺和诺德的糖尿病药物Ozempic使用相同的活性成分，于2021年获得批准。该公司报告说，在12月Zepbound上市的头几周， ，销售额达1.758亿美元。根据这项研究的数据，经过13周的治疗，VK2735帮助患者实现了高达14.7%的平均体重减轻。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","NVO","IE0009355771.USD","LU0097036916.USD","LU0882574055.USD","LU1894683264.USD","LU1804176565.USD","SG9999001176.SGD","LU0321505868.SGD","LU0114720955.EUR","LU1551013425.SGD","LU0820561818.USD","LLY","LU2112291526.USD","LU0079474960.USD","IE0002141913.USD","BK4592","LU0109394709.USD","LU1551013342.USD","IE00BJLML261.HKD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1878469433.USD","SG9999011175.SGD","GB00BDT5M118.USD","LU0096364046.USD","AMGN","BK4581","LU0385154629.USD","LU1061106388.HKD","PFE","GPCR","LU0943347566.SGD","LU1712237335.SGD","BK4588","LU1623119135.USD","LU1066051498.USD","LU0256863811.USD","LU0471298694.HKD","IE00BJJMRZ35.SGD","LU1894683348.USD","OPK","LU0466842654.USD","BK4532","IE0004445239.USD","LU1069344957.HKD","LU0882574139.USD","LU2242652126.USD","IE00BKVL7J92.USD","ALT"],"gpt_icon":1},{"id":"1167017119","title":"罗氏口服减肥药临床试验取得积极结果！减肥药概念股闻讯下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1167017119","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1167017119?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:41","pubTimestamp":1721223718,"startTime":"0","endTime":"0","summary":"7月17日，罗氏控股涨近8%，公司称其口服减肥药临床试验取得积极结果；受此消息影响，$诺和诺德(NVO)$、$礼来(LLY)$、Viking减肥药概念股集体下挫。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1804176565.USD","NVO","LU0882574055.USD","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","BK4534","VKTX","LLY","LU0820561909.HKD","BK4585","LU0471298694.HKD","LU0466842654.USD","LU0122379950.USD","LU0689472784.USD","IE00BK4W5L77.USD","RHHBY","LU0096364046.USD","LU1061106388.HKD","IE00BJLML261.HKD","LU0097036916.USD"],"gpt_icon":0},{"id":"2452151905","title":"“诺礼”惊出一身冷汗！罗氏口服减肥药临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2452151905","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452151905?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:20","pubTimestamp":1721222413,"startTime":"0","endTime":"0","summary":"罗氏旗下Genentech表示，其口服GLP-1受体激动剂CT-996在1期临床试验中的四周内平均体重减轻了约6%。","market":"sg","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152309.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“诺礼”惊出一身冷汗！罗氏口服减肥药临床试验取得积极结果","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","NVO","BK1576","BK1141","LLY","BK4007","VKTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.0539},{"period":"1month","weight":-0.0611},{"period":"3month","weight":0.0564},{"period":"6month","weight":0.2612},{"period":"1year","weight":0.6447},{"period":"ytd","weight":0.2884}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.017},{"period":"3month","weight":0.0957},{"period":"6month","weight":0.1347},{"period":"1year","weight":0.2192},{"period":"ytd","weight":0.1651}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S于1989年成立，由两家丹麦公司，诺德根措夫特A/S和Novo工业A/S的合并而成。诺和诺德是一家全球性医疗保健公司，糖尿病治疗的全球领先者。公司拥有业界最广泛的糖尿病产品组合，其中包括新一代胰岛素，现代的完整产品组合，以及作为一个人每日一次的GLP-1类似物之一。此外，诺和诺德在血友病关怀，生长激素疗法和激素替代疗法中也处于领先地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.534884,"avgChangeRate":0.122207},{"month":2,"riseRate":0.604651,"avgChangeRate":0.027007},{"month":3,"riseRate":0.465116,"avgChangeRate":0.01259},{"month":4,"riseRate":0.627907,"avgChangeRate":0.016402},{"month":5,"riseRate":0.545455,"avgChangeRate":0.017073},{"month":6,"riseRate":0.704545,"avgChangeRate":0.027554},{"month":7,"riseRate":0.5,"avgChangeRate":0.005601},{"month":8,"riseRate":0.511628,"avgChangeRate":0.000647},{"month":9,"riseRate":0.581395,"avgChangeRate":0.000639},{"month":10,"riseRate":0.511628,"avgChangeRate":-0.000902},{"month":11,"riseRate":0.627907,"avgChangeRate":0.028932},{"month":12,"riseRate":0.744186,"avgChangeRate":0.054828}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}